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Abstract
Introduction: The goal of this study was to identify serum markers that are modulated by treatment with
golimumab with or without methotrexate (MTX) and are associated with clinical response.
Methods: Sera were collected at weeks 0 and 4 from a total of 336 patients (training dataset, n = 100; test dataset,
n = 236) from the GO-FORWARD study of patients with active rheumatoid arthritis despite MTX. Patients were
randomly assigned to receive placebo plus MTX; golimumab, 100 mg plus placebo; golimumab, 50 mg plus MTX;
or golimumab, 100 mg plus MTX. Subcutaneous injections were administered every 4 weeks. Samples were tested
for select inflammatory, bone, and cartilage markers and for protein profiling using multianalyte profiles.
Results: Treatment with golimumab with or without MTX resulted in significant decreases in a variety of serum
proteins at week 4 as compared with placebo plus MTX. The American College of Rheumatology (ACR) 20, ACR 50,
and Disease Activity Score (DAS) 28 responders showed a distinct biomarker profile compared with nonresponding
patients.
Conclusions: ACR 20 and ACR 50 responders among the golimumab/golimumab + MTX-treated patients had a
distinct change from baseline to week 4 in serum protein profile as compared with nonresponders. Some of these
changed markers were also associated with multiple clinical response measures and improvement in outcome
measures in golimumab/golimumab + MTX-treated patients. Although the positive and negative predictive values
of the panel of markers were modest, they were stronger than C-reactive protein alone in predicting clinical
response to golimumab.
Trial registration: http://ClinicalTrials.gov identification number: NCT00264550.
Introduction
Rheumatoid arthritis (RA) is characterized by the presence
of proinflammatory cytokines, tissue-destructive enzymes,
and bone degradation products in the blood, synovium,
and joints. The success of antitumor necrosis factor a
(anti-TNF-a) therapies in controlling RA indicates that
TNF-a is a key controlling factor in driving inflammation
and associated bone degradation. Several markers are
known to be related to disease progression in RA (C-reac-
tive protein (CRP), erythrocyte sedimentation rate (ESR),
anti-cyclic citrullinated peptide (anti-CCP) antibodies,
rheumatoid factor, and osteoprotegrin-receptor activator
of nuclear factor (NF)- B ligand) [1-3], but better clinical
response markers are needed to assist rheumatologists in
selecting treatments most likely to benefit any particular
patient. Several studies have shown that reductions in
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factor [5,8,9] are associated with improvements in clinical
response in patients treated with anti-TNF-a therapies.
Baseline levels of intracellular adhesion molecule-1
(ICAM-1) and cartilage oligomeric matrix protein
(COMP) have been associated with response in RA
patients treated with adalimumab [6]. More recent studies
have identified that apolipoprotein A1 [10], serpin, and
S-100-related proteins are associated with response to
infliximab treatment [11]. We also recently showed that
changes in E-selectin, interleukin (IL)-18, serum amyloid
A, and matrix metalloproteinase-9 (MMP-9) are associated
with improvement in clinical response measures in a
phase 2 study of patients with active RA despite metho-
trexate (MTX) therapy, who were treated with golimumab
(a human monoclonal antibody to TNF-a) [12]. Overall,
these studies included small numbers of patients and lim-
ited datasets, making it difficult to test the reproducibility
or predictive power of these preliminary results; however,
several of these studies showed weak associations (r values
or odds ratios) between the identified biomarkers and spe-
cific clinical response measures.
In the current study, our primary objective was to
evaluate approximately 100 different serum proteins by
using multiplex and single-plex assay platforms
(enzyme-linked immunosorbent assay (ELISA) and
Luminex) to identify markers modulated by golimumab
treatment in patients with RA. The secondary objective
was to determine whether any of these markers is
strongly associated with multiple clinical measures in
response to golimumab. Our last objective was to evalu-
ate whether the preliminary test results could be con-
firmed in a larger set of patients from the same study.
Materials and methods
The details of the GO-FORWARD study have been pre-
viously published [13]. In brief, patients with active RA
despite MTX were randomly assigned in a 3:3:2:2 ratio to
receive placebo plus MTX (group 1); golimumab, 100 mg
plus placebo (group 2); golimumab, 50 mg plus MTX
(group 3); or golimumab, 100 mg plus MTX (group 4).
A tw e e k1 6 ,p a t i e n t si ng r o u p s1 ,2 ,o r3w h oh a dl e s s
than 20% improvement from baseline in tender and swol-
len joints entered early escape. Patients in group 1
received golimumab, 50 mg, while continuing MTX;
patients in group 2 received MTX while continuing goli-
mumab, 100 mg; and patients in group 3 had their goli-
mumab dose increased from 50 to 100 mg while
continuing MTX. Patients who were originally assigned
to group 4 were not eligible for treatment adjustment.
As reported previously [13], this study was conducted
in accordance with the Declaration of Helsinki and good
clinical practices. The protocol was reviewed and
approved by each site’s institutional review board or
ethics committee. All patients provided written informed
consent before undergoing study-related procedures.
Sites were randomly chosen for biomarker testing.
Biomarker analysis was conducted on an initial subset
of 100 consecutively enrolled patients from the
GO-FORWARD study (hereafter referred to as the
“training” subset). Samples from an additional 236 con-
secutively enrolled patients assigned to golimumab plus
placebo and golimumab plus MTX groups (hereafter
referred to as the “test” s u b s e t )f r o mt h i ss a m es t u d y
were subsequently analyzed to evaluate the reproducibil-
ity of the training set results. Patient sera were collected
at weeks 0, 4, 14, and 24. Samples were tested for
selected markers by using Luminex and ELISA plat-
forms by Quintiles Laboratories (Marietta, GA) and
Pacific Biometrics (Seattle, WA). The individual markers
selected for these analyses included bone alkaline
phosphatase, COL 2-3/4C long neoepitope, deoxypyridi-
noline, hyaluronic acid, IL- 6 ,I L - 8 ,I C A M - 1 ,M M P - 3 ,
N-terminal propeptide of type 1 procollagen (P1NP),
osteocalcin, pyridinoline, TNF-a, and vascular endothe-
lial growth factor (VEGF). The samples also were ana-
lyzed by Rules Based Medicine (Austin, TX) using the
HumanMAP version 1.6 protein-profiling analysis [14].
The HumanMAP profiling analysis included 92 analytes.
Some of the selected markers listed above were also
included in this profile analysis (IL-6, IL-8, ICAM-1,
MMP-3, TNF-a, and VEGF).
Only markers for which 20% or more of samples were
above the lower limit of quantification were included in
the subsequent data analysis. Biomarker data were log2
transformed. Changes from baseline were tested by
using one-sample t tests. Pearson correlation was used
to measure the association between biomarker levels
and clinical response. Logistic regression models were
used to test for the association between biomarker levels
and clinical response measures and patient reported
outcomes. Clinical response was evaluated by using the
American College of Rheumatology response criteria
(ACR 20 and ACR 50) and the Disease Activity Score
using 28 joints (DAS 28). Health-related quality of life
was evaluated using the 36-question Short Form Survey
(SF-36). Fatigue was evaluated using the Functional
Assessment of Chronic Illness Therapy-Fatigue (FACIT-
F). Prediction models were developed by using logistic
regression. Model accuracy (sensitivity, specificity, nega-
tive predictive value (NPV), and positive predictive value
(PPV)) was estimated by using cross validation.
To account for multiple testing, a false discovery rate
(FDR) analysis was performed. The FDR analysis was
used to define a P-value threshold at which the FDR
would be approximately 5% to 10% and it accounted for
the fact that the biomarkers studied were not indepen-
dent but showed marker-to-marker correlations.
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Of the 107 biomarkers evaluated, 78 (73%) met the pre-
specified criteria for inclusion in the data analysis (that
is, 20% or more of all samples were above the lower
limit of quantification for the assay). As discussed in
more detail later, we found significant relations to effi-
cacy for biomarkers in the following general categories:
acute phase reactants (a1-antitrypsin, CRP, haptoglobin,
serum amyloid P, von Willebrand factor), bone metabo-
lism factors (hyaluronic acid, pyridinoline, P1NP),
coagulation factors (lipoprotein(a), plasminogen activa-
tor inhibitor-1 (PAI-1), factor VII), hematologic factors
(complement 3, ferritin, myoglobin), inflammatory mar-
kers (CD40, ENRAGE (S100A12), epithelium-derived
neutrophil-activating protein 78 (ENA-78), IL-1 receptor
agonist, IL-6, IL-16, ICAM-1, macrophage inflammatory
protein (MIP)-1a,M I P - 1 b,M M P - 3 ,m o n o c y t ec h e m o -
tactic protein-1 (MCP-1), monocyte/macrophage-derived
chemokine (MDC or CCR-4), myeloperoxidase, tissue
inhibitor of metalloproteinases-1 (TIMP-1), TNF recep-
tor 2, VEGF), metabolic factors (adiponectin, apolipo-
protein A1, apolipoprotein C3, leptin), and other factors
(thyroxine-binding globulin, basic fibroblast growth
factor (bFGF), carcinoembryonic antigen, stem cell fac-
tor, insulin, cancer antigen 125, serum glutamic oxaloa-
cetic transaminase (SGOT), sex hormone-binding
globulin (SHBG)).
Baseline characteristics
Baseline characteristics for the training and test subsets
are displayed in Table 1. The test subset was generally
similar to the training subset, although the golimumab
50 mg plus MTX group in the training subset had a
higher proportion of women than the other treatment
groups in the training subset.
In the test subset, mean baseline marker levels were
similar among the treatment groups, with the exception
of levels of myeloperoxidase, thyroxine-binding globulin,
vascular cellular adhesion molecule-1, and TNF-a (data
not shown). In the training subset, differences among the
treatment groups were observed in mean myeloperoxi-
dase and prostatic acid phosphatase levels only (data not
shown). These treatment-group differences did not affect
the results of the subsequent analyses. Additionally, bio-
marker levels were generally similar between responders
and nonresponders at baseline (data not shown).
Changes from baseline in biomarker levels
In the training dataset, significantly greater decreases
from baseline to week 4 (P < 0.01) in the mean levels of
14 markers as well as an increase in P1NP were
observed in the golimumab plus MTX groups compared
with the placebo plus MTX group. Log2 transformed
values for these markers at baseline and week 4 are
shown in Figure 1a. Markers with significant changes
included a metabolic factor (leptin), acute-phase reac-
tants (a1-antitrypsin, von Willebrand factor, serum amy-
loid P, haptoglobin, and CRP), a coagulation factor
(lipoprotein(a)), a bone-metabolism factor (P1NP),
inflammatory markers (ICAM-1, MMP-3, ENRAGE, and
TIMP-1), a hematologic factor (complement 3), and
thyroxine-binding globulin.
In the test dataset, a larger set of markers significantly
changed after 4 weeks (Figure 1b). In addition to the
markers identified earlier in the training dataset, changes
were observed in inflammatory markers (MDC, MIP-1a,
TNF receptor 2, IL-18, MCP-1, IL-8, MIP-1b, CD40,
ENA 78, VEGF, myeloperoxidase, IL-16, IL-1 receptor
agonist), coagulation factors (lipoprotein(a), factor VII,
PAI-1), metabolic factors (apolipoprotein A1, adiponec-
tin), hematologic factors (ferritin, myoglobin), and other
factors (insulin, cancer antigen 125, SGOT, and SHBG).
In both datasets, less substantial changes in these mar-
kers were observed in the golimumab monotherapy
treatment group as compared with the golimumab plus
MTX groups, indicating a stronger modulation of the
overall biomarker response for golimumab treatment in
combination with MTX compared with golimumab
monotherapy.
Distinct changes in biomarker profiles were observed
for golimumab-treated patients who were ACR 20
responders and nonresponders at week 14 (Figure 2). In
the training dataset, ACR 20 responders had signifi-
cantly greater decreases from baseline to week 4 in 16
markers compared with nonresponders. Significant dif-
ferences between responders and nonresponders also
were found in the test dataset for seven of these mar-
kers. Apolipoprotein C3, bFGF, and VEGF levels were
the only markers for which significant differences were
observed between ACR 20 responders and nonrespon-
ders in the test dataset but not in the training dataset
(Figure 2). Similar markers were modulated between
ACR 20 and ACR 50 responders and nonresponders.
Associations between biomarker levels and clinical
endpoints in golimumab/golimumab plus
MTX-treated patients
Associations (odds ratio values) between biomarker
levels and several clinical endpoints are summarized in
Table 2. In the training dataset, only baseline levels of
two markers (pyridinoline and von Willebrand factor)
were significantly associated with selected clinical
response measures in golimumab-treated patients. Base-
line von Willebrand factor levels were associated with
ACR 20 and ACR 50 responses at week 14, whereas
baseline levels of pyridinoline were associated with ACR
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week 4 in selected markers (including a1-antitrypsin,
complement 3, ENRAGE, haptoglobin, hyaluronic acid,
IL-8, IL-16, MMP-3, pyridinoline, PAI-1, serum amyloid
P, and thyroxine-binding globulin) were also associated
with clinical response measures at week 14.
In the test dataset, baseline levels of apolipoprotein
C 3 ,h y a l u r o n i ca c i d ,I L - 6 ,I L - 8 ,M M P - 3 ,a n dm y e l o p e r -
oxidase were associated with ACR 20, ACR 50, and
DAS 28 responses at week 14. An evaluation of biomar-
ker changes from baseline to week 4 yielded a set of
markers similar to that identified in the training dataset
(including a1-antitrypsin, apolipoprotein C3, bFGF, car-
cinoembryonic antigen, CRP, ENRAGE, haptoglobin,
hyaluronic acid, IL-6, IL-16, ICAM-1, lipoprotein (a),
MMP-3, MIP-1a, serum amyloid P, stem cell factor,
TIMP-1, and VEGF) that were associated with clinical
response at week 14 (Table 2).
Table 1 Baseline characteristics for training and test datasets
Placebo + MTX Golimumab
100 mg + placebo
Golimumab
50 mg + MTX
Golimumab
100 mg + MTX
Total
Training dataset
Number 21 30 21 28 100
Age (years) 50 ± 12
(24-76)
50 ± 12
(22-71)
53 ± 11
(25-68)
52 ± 9
(38-76)
51 ± 11
(22-76)
Weight (kg) 70 ± 13
(47-97)
72 ± 15
(47-104)
69 ± 18
(43-108)
75 ± 22
(47-120)
72 ± 17
(43-120)
Sex (% men) 10% 20% 10% 21% 16%
Race (% Caucasian) 76% 67% 67% 75% 71%
CRP (μg/ml) 1.97 ± 2.54
(0.3-10.8)
2.16 ± 2.77
(0.3-11.7)
1.20 ± 1.53
(0.3-7.0)
1.38 ± 1.44
(0.3-6.2)
1.70 ± 2.18
(0.30-11.7)
Swollen joint count 13.0 ± 5.7
(5-26)
13.9 ± 10.4
(5-51)
12.5 ± 9.2
(4-48)
14.2 ± 9.6
(5-43)
13.5 ± 9.0
(4-51)
Tender joint count 21.3 ± 12.3
(6-62)
21.4 ± 13.1
(5-58)
23.2 ± 16.8
(4-63)
24.1 ± 13.4
(6-53)
22.5 ± 13.7
(4-63)
FACIT-F (0-52) 26 ± 11
(4-50)
26 ± 10
(4-50)
27 ± 12
(12-50)
26 ± 11
(4-50)
SF-36 mental component summary score (0-100) 44 ± 9
(20-61)
45 ± 11
(26-61)
44 ± 11
(24-62)
44 ± 10
(20-62)
SF-36 physical component summary score (0-100) 30 ± 8
(17-54)
32 ± 9
(18-51)
33 ± 8
(19-52)
31 ± 8
(17-54)
Test dataset
Number N/A 102 68 66 236
Age (years) 50 ± 11
(21-74)
50 ± 11
(18-79)
50 ± 10
(23-72)
50 ± 11
(18-79)
Weight (kg) 74 ± 17
(42-135)
74 ± 18
(39-146)
71 ± 17
(40-136)
73 ± 17
(39-146)
Sex (% men) 22% 22% 21% 22%
Race (% Caucasian) 82% 76% 82% 81%
CRP (μg/ml) 1.84 ± 2.27
(0.3-15.1)
2.23 ± 2.54
(0.3-11.5)
1.98 ± 2.68
(0.3-16.8)
1.99 ± 2.47
(0.3-16.8)
Swollen/tender joint count 41.0 ± 21.6
(10-88)
47.4 ± 23.0
(10-105)
41.7 ± 21.0
(9-100)
43.0 ± 21.9
(9-105)
Swollen joint count 15.0 ± 10.6
(4-59)
18.0 ± 12.3
(4-53)
14.8 ± 9.7
(4-45)
15.8 ± 10.9
(4-59)
Tender joint count 26.0 ± 15.9
(5-68)
29.3 ± 15.3
(5-68)
27.0 ± 15.0
(4-62)
27.2 ± 15.5
(4-68)
FACIT-F (0-52) 29 ± 11
(5-50)
27 ± 11
(6-50)
26 ± 10
(6-47)
27 ± 11
(5-50)
SF-36 mental component summary score (0-100) 44 ± 12
(19-73)
44 ± 11
(19-73)
43 ± 12
(17-68)
43 ± 11
(17-73)
SF-36 physical component summary score (0-100) 31 ± 9
(15-54)
30 ± 8
(16-49)
29 ± 8
(12-46)
30 ± 8
(12-54)
Values are expressed as mean ± standard deviation (range), unless otherwise indicated. CRP, C-reactive protein; FACIT-F, Functional Assessment of Chronic Illness
Therapy-Fatigue; MTX, methotrexate; SF-36, 36-question Short Form Survey.
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combination of markers
With a logistic regression analysis, the best combination
of markers (based on change from baseline to week 4)
that were associated with ACR 20 and ACR 50
responses at week 14 is listed in Table 3. This combina-
tion includes seven markers, several of which have not
been shown to be associated with RA or response to
anti-TNF-a treatment. The change from baseline to
week 4 in hyaluronic acid and apolipoprotein C3 were
the strongest predictors of ACR 20 response at week
14, followed by baseline levels of rheumatoid factor.
Only three of these markers (hyaluronic acid, apolipo-
protein C3, and IL-16) plus haptoglobin, swollen and
tender joint count at baseline, and anti-CCP antibodies
were identified as important factors in the prediction of
ACR 50 response. Despite being included as one part of
the ACR-response criteria, CRP was important for ACR
20 response prediction, but not for ACR 50 response.
The NPV and PPV values for CRP alone were lower
than the best combination of markers for prediction of
ACR 20 and ACR 50 responses, indicating that it is
possible for a panel of markers to outperform CRP in
monitoring the responsiveness of patients to anti-TNF-
a treatment. ESR analyses were slightly less predictive
of ACR 20 or ACR 50 responses than was CRP (data
not shown).
Associations between biomarker levels and health-related
quality-of-life outcomes
We examined the associations between biomarker levels
and patient reported measures of health-related quality
of life (SF-36) and fatigue (FACIT-F). We previously
showed that RA patients treated with golimumab with
or without MTX showed significantly greater improve-
ment from baseline in SF-36 physical and mental com-
ponent scores (PCS and MCS) and FACIT-F scores
compared with placebo plus MTX at week 14 [15]. In
the current study, although several significant associa-
tions were found between selected biomarker levels and
FACIT-F and SF-36 scores in the training dataset
(Table 4), most of these findings were not reproduced
in the test dataset, possibly because the original sample
size was very limited. In the combined dataset, associa-
tions between lower baseline levels of a-antitrypsin,
ICAM-1, TIMP-1, and von Willebrand factor and
improvement in PCS at week 14 were observed. Low
levels of ENRAGE at baseline were also associated with
improvement in FACIT-F scores at week 14. Decreases
from baseline to week 4 in CRP, ENRAGE, and IL-6
levels were associated with improvement in PCS, and
decreases in MMP-3 levels were associated with
improvement in MCS.
Discussion
In this study, we evaluated an array of 107 serum pro-
teins and showed that golimumab treatment with or
without MTX is effective in modulating certain acute
phase reactants (CRP, a1-antitrypsin, von Willebrand
factor, and haptoglobin), inflammatory markers (IL-6
and ENRAGE), and other selected proteins (bFGF, apoli-
protein C3, and serum amyloid P) in two separate data-
sets from the same study of patients with inadequate
responders to MTX. The robustness of the analyses can
be attributed to the minimal variability observed
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Figure 1 Biomarker heatmaps for significant differences
between baseline and week 4 for test and training datasets.
Heatmaps representing biomarkers that were significantly different
between baseline and week 4 for any of the treatment group for
the training (a) and test (b) datasets. In the test dataset, only
patients treated with golimumab were evaluated. Colors represent
ranges of mean log2 transformed biomarker levels at each time
point (see legend for ranges).
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these proteins (Rules-Based Medicine, Luminex, and
ELISA). Thus, this provided us with a high level of con-
fidence in the reproducibility of the changes and asso-
ciations observed.
In the golimumab-treated patients, ACR 20 and
ACR 50 responders displayed a distinct serum protein
signature as compared with nonresponders, which
confirms the importance of the significant markers
(IL-6, CRP, haptoglobin, IL-16, VEGF, bFGF,
ENRAGE, hyaluronic acid, and MMP-3) in the
rheumatologic disease processes. Further, strong
associations were shown between the levels of some
of these markers (at baseline and changes from base-
line to week 4) and response to multiple clinical mea-
sures (ACR 20, ACR 50, and DAS 28) after 14 weeks
of treatment. In this study, we were also able to show
significant associations between changes in measures
of patient reported outcomes (SF-36 and FACIT-F)
and the changed levels of some of the markers in
patients treated with golimumab. The results revealed
a link between improvements in disease markers of
inflammation and improvement in patient reported
outcome measures.
Vascular endothelial growth factor
Matrix metalloproteinase-3
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
N
R
R=Responders; N=Non-responders
*p<0.05, **p<0.01, †p<0.001
N
Interleukin-16
Interleukin-6
Hyaluronic acid
Haptoglobin
Basic fibroblast growth factor
ENRAGE (S100A12)
C-reactive protein
Apolipoprotein C3
Test Subset
Tumor necrosis factor receptor II
Thyroxine binding globulin
Serum amyloid P
Plasminogen activator inhibitor-1
Myeloperoxidase
Matrix metalloproteinase-3
Lipoprotein (a)
Interleukin-16
Interleukin-6
Hyaluronic acid
Haptoglobin
EN RAGE (S100A12)
Complement 3
C-reactive protein
α-1 antitrypsin
Training Subset ACR50 ACR20
-2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5
2
2
0
8
7
b
2
2
0
8
8
-2.5 -2 -1.5 -1 -0.5 0 0.5
†
†
†
†
†
†
†
†
†
†
†
†
**
** **
**
**
**
**
**
** **
** **
** **
**
**
**
**
** **
**
*
*
*
* *
* *
*
*
*
*
*
*
*
*
*
Figure 2 Comparison of biomarkers significantly different between ACR responders and nonresponders for golimumab-treated
patients. Mean ± SD comparison of biomarkers (log
2 transformed) that were significantly different between ACR 20 and ACR 50 responders and
nonresponders for golimumab-treated patients in the Training and Test Subsets.
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markers in perpetuating disease in RA patients. Markers
such as CRP [16], haptoglobin, apolipoprotein C3 [17],
and ENRAGE [18] have been associated with the early,
acute phase responses that occur in RA. Additionally,
Charles-Schoeman and colleagues [17] showed that
patients with RA with proinflammatory high-density
lipoprotein (HDL) exhibit increases in haptoglobin and
apolipoprotein levels as compared with patients with
anti-inflammatory HDL.
In contrast to the acute-phase response markers, IL-6,
IL-16, fibroblast growth factor (FGF), VEGF, hyaluronic
acid, and MMP-3 have all been linked to the structural
changes that occur during disease progression in RA. IL-6
levels in synovial fluid have previously been associated
with local joint-activity score [19] in addition to swollen/
tender joint counts in RA [20]. Recent data by Warstat et
al. [21] showed that synovial fibroblasts from RA patients
stimulated with transforming growth factor-b1 on laminin
111 exhibit increases in IL-16 gene expression as com-
pared with osteoarthritis synovial fibroblasts. FGF has
been shown to have a role in both matrix synthesis and
degradation. Elevated levels of FGF in cartilage have been
associated with not only arthritic disease leading to joint
destruction [22], but also in mediating cartilage regenera-
tion [23]. VEGF expression is induced by hypoxic condi-
tions that occur in the RA joint, and osteoclast expression
of VEGF is mediated through NF-B [24]. Further, fibro-
blast-like synoviocytes under hypoxic conditions exhibit
elevated MMP-3 levels [25], and a polymorphism in the
MMP-3 gene has been shown to be associated with radio-
graphic progression [26]. Elevated levels of hyaluronic acid
have been observed in serum from RA patients, and this
correlated with clinical parameters [27,28]. Together, this
information provides support for the role of these markers
in RA disease pathogenesis.
Table 2 Associations between biomarker levels (baseline
and changes from baseline to week 4) and clinical
measures (ACR 20, ACR 50, and DAS 28 responses) at
week 14 for golimumab/golimumab + MTX training and
test datasets
ACR 20 ACR 50 DAS 28
OR P OR P OR P
Training subset
Baseline
Pyridinoline 0.101 0.004 0.383 NS 0.150 NS
von Willebrand factor 0.444 0.048 0.366 0.026 0.420 NS
Change from baseline to
week 4
a1-Antitrypsin 0.025 0.009 1.021 NS 0.138 NS
Complement 3 0.007 0.006 0.707 NS 0.324 NS
ENRAGE (S100A12) 0.455 0.015 0.841 NS 0.381 0.030
Haptoglobin 0.131 0.003 0.693 NS 0.276 0.033
Hyaluronic acid 0.343 0.006 0.975 NS 0.511 NS
Interleukin-8 0.483 NS 0.472 0.020 0.572 NS
Interleukin-16 0.121 0.012 1.041 NS 0.096 0.015
Matrix metalloproteinase-3 0.318 0.008 1.102 NS 0.283 NS
Plasminogen activator-1 0.114 0.041 0.713 NS 0.442 NS
Pyridinoline 3.744 NS 0.212 0.044 23.610 NS
Serum amyloid P 0.057 0.006 0.650 NS 0.075 0.035
Thyroxine-binding
globulin
0.008 0.008 2.093 NS 0.221 NS
Test subset
Baseline
Apolipoprotein C3 0.753 NS 0.510 0.006 0.930 NS
Hyaluronic acid 1.347 0.001 1.228 0.037 1.102 NS
Interleukin-6 1.199 0.024 1.232 0.027 1.052 NS
Interleukin-8 0.880 NS 0.970 NS 0.802 0.042
Matrix metalloproteinase-3 1.240 0.026 1.181 NS 1.087 NS
Myeloperoxidase 0.821 NS 0.934 NS 0.694 0.020
Change from baseline to
week 4
a1-Antitrypsin 0.505 NS 0.298 0.035 0.301 0.033
Apolipoprotein C3 2.191 0.014 1.681 NS 1.741 NS
Basic fibroblast growth
factor
0.353 0.007 0.484 0.042 0.424 0.012
Carcinoembryonic antigen 2.674 NS 1.89 NS 3.891 0.020
C-reactive protein 0.714 <0.001 0.652 <0.001 0.728 0.002
ENRAGE (S100A12) 0.642 0.005 0.568 0.001 0.767 NS
Haptoglobin 0.497 0.004 0.417 <0.001 0.474 0.008
Hyaluronic acid 0.513 <0.001 0.514 <0.001 0.699 0.017
Interleukin-6 0.623 <0.001 0.665 <0.001 0.733 0.003
Interleukin-16 0.371 0.007 0.234 <0.001 0.422 0.029
Intracellular adhesion
molecule-1
0.654 NS 0.673 NS 0.468 0.030
Lipoprotein (a) 0.727 NS 0.460 0.045 0.748 NS
Matrix metalloproteinase-3 0.539 0.001 0.570 0.005 0.673 0.043
Table 2 Associations between biomarker levels (baseline
and changes from baseline to week 4) and clinical mea-
sures (ACR 20, ACR 50, and DAS 28 responses) at week
14 for golimumab/golimumab + MTX training and test
datasets (Continued)
Macrophage inflammatory
protein 1-a
0.687 NS 0.454 0.041 0.903 NS
Serum amyloid P 0.628 NS 0.304 0.015 0.346 0.025
Stem cell factor 2.239 0.028 1.521 NS 1.383 NS
Tissue inhibitor of
metalloproteinases-1
0.595 NS 0.264 0.035 0.603 NS
Vascular endothelial
growth factor
0.419 0.009 0.326 0.004 0.307 0.002
Only biomarkers are shown for which P < 0.05 for associations with ACR 20 or
ACR 50 responses at each point. ACR, American College of Rheumatology;
DAS, disease activity score; OR, odds ratio; MTX, methotrexate; NS, not
significant.
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Page 7 of 11Table 3 Logistic regression predictive models results by using changes in biomarker levels from baseline to week 4
and clinical response at week 14. Model included training and test datasets combined
ACR 20
CRP-only model
a (n = 308)
True/Predicted NR R Accuracy
NR 35 115 Specificity = 23%
R 16 142 Sensitivity = 90%
Predictive value NPV = 68% PPV = 55%
Threshold = -0.35
Biomarker model
a (n = 308)
True/Predicted NR R Accuracy
NR 62 88 Specificity = 41%
R 16 142 Sensitivity = 90%
Predictive value NPV = 79% PPV = 61%
Threshold = -0.35
Predictors from biomarker model
b Weight Odds ratio Multivariate P value
Hyaluronic acid 0.60 1.82 0.0001
Apolipoprotein C3 -0.98 0.38 0.003
Rheumatoid factor positive at baseline -0.91 0.4 0.014
Basic fibroblast growth factor 0.72 2.05 0.023
Interleukin-16 0.83 2.29 0.031
Interleukin-6 serum 0.21 1.23 0.049
C-reactive protein 0.17 1.19 0.062
ACR 50
CRP-only model
a (n = 308)
True/Predicted NR R Accuracy
NR 108 116 Specificity = 48%
R 17 67 Sensitivity = 80%
Predictive Value NPV = 86% PPV = 36%
Threshold = -1.3
Biomarker model
a (n = 308)
True/Predicted NR R Accuracy
NR 137 87 Specificity = 61%
R 17 67 Sensitivity = 80%
Predictive value NPV = 89% PPV = 44%
Threshold = -1.2
Predictors from biomarker model
b Weight Odds ratio Multivariate P value
Hyaluronic acid 0.53 1.70 0.001
Haptoglobin 0.79 2.2 0.001
Apolipoprotein C3 -0.94 0.39 0.007
Interleukin-16 1 2.72 0.014
STJC at baseline 0.17 1.19 0.015
Anti-CCP antibodies -0.82 0.44 0.044
aAll biomarker values were log transformed before inclusion in the models. Model accuracy (sensitivity, specificity, NPV, PPV) was estimated by using cross
validation.
bWeights are the coefficients in the logistic regression model. Odds ratios are the exponential of the weights. Multivariate P values are the P values
when all of the terms are included in the model. ACR, American College of Rheumatology; anti-CCP, cyclic citrullinated peptide; CRP, C-reactive protein; NPV,
negative predictive value; NR, nonresponder; PPV, positive predictive value; R, responder; STJC, swollen and tender joint count.
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early changes from baseline to week 4 values) was
superior to CRP alone in predicting response to golimu-
mab treatment. These markers included CRP, hyaluronic
acid, bFGF, apolipoprotein C3, rheumatoid factor, IL-16,
and IL-6; however, the NPV and PPV values were not
indicative of a strong prediction of response. Results
published by Hueber et al. [29] identified a 24-serum
marker signature that was also weakly predictive of
response to etanercept treatment. Further, with the
exception of IL-6, none of these markers overlapped
with the markers that we have identified in the current
study.
Several limitations existed in the study. First, the num-
ber of patients in the training dataset was small, making
it difficult to reproduce findings in the larger test data-
set. Also, it would have been useful to have an earlier
collection of samples prior to week 4, enabling identifi-
cation of earlier, and perhaps stronger, associations
between biomarker levels and clinical measures of
response. We also observed very low CRP values in
patients, and this made it difficult to show further
reductions and correlations. An earlier collection of
samples would have led us to a better understanding of
the fluctuations of specific markers in response to treat-
ment and in relation to changes in disease activity.
Lastly, a stronger analysis might have been possible by
including profiling of RNA from peripheral blood
mononuclear cells, enabling the evaluation of an even
larger number of analytes and the inclusion of other key
molecules in the TNF-a pathway [30].
Conclusions
Clearly, a clinical response to golimumab involves mod-
ulation of several RA disease processes, including those
involved in the acute and inflammatory phase of disease,
as well as downstream aspects relating to bone and car-
tilage metabolism and destruction. The results of this
study from two separate datasets showed strong associa-
tions between selected biomarker levels and improve-
ment in a variety of clinical-response measures after
treatment with golimumab. Baseline levels of markers
were not consistently associated with future response to
golimumab therapy. The best set of markers associated
with response to golimumab treatment included week-4
changes from baseline; however, even these markers
were unable to achieve high enough specificity and sen-
sitivity to be routinely useful predictors. Thus, additional
testing of serum and other types of markers from other
studies will be needed to identify additional molecules
that can either be added to strengthen this panel or be
used independently as predictive markers in the man-
agement of patients with RA who are treated with anti-
TNF-a therapies.
Abbreviations
ACR: American College of Rheumatology; bFGF: basic fibroblast growth
factor; CCP: cyclic citrullinated peptide; CRP: C-reactive protein; COMP:
cartilage oligomeric matrix protein; DAS: Disease Activity Score; ELISA:
enzyme-linked immunosrobent assay; ENA: epithelium-derived neutrophil-
activating protein; ESR: erythrocyte sedimentation rate; FACIT-F: Functional
Assessment of Chronic Illness Therapy -Fatigue; FDR: false discovery rate;
FGF: fibroblast growth factor; ICAM: intracellular adhesion molecule; IL:
interleukin; MCP: monocyte chemotactic protein; MDC: monocyte/
macrophage-derived chemokine or CCR-4; MCS: mental component score;
MIP: macrophage inflammatory protein; MMP: matrix metalloproteinase;
MTX: methotrexate; NF: nuclear factor; NPV: negative predictive value; P1NP:
Table 4 Odds ratios for associations between biomarker
levels (baseline and changes from baseline to week 4)
and outcome measures of fatigue (FACIT-F) and health-
related quality of life (SF-36) at week 14 for the training
and test golimumab/golimumab + MTX datasets
FACIT-F SF-36 PCS SF-36 MCS
OR P OR P OR P
Training subset
Baseline
von Willebrand factor 0.380 0.021 0.427 0.039 0.370 0.019
Change from baseline to week
4
ENRAGE (S100A12) 0.578 0.053 0.549 0.044 0.603 0.070
Matrix metalloproteinase-3 0.529 0.041 0.621 0.122 1.000 0.999
Test subset
Baseline
Matrix metalloproteinase-3 1.233 0.035 0.922 0.409 0.972 0.775
Tissue inhibitor of
metalloproteinase-1
0.925 0.843 0.375 0.017 0.798 0.567
Change from baseline to week
4
C-reactive protein 0.879 0.122 0.772 0.003 0.833 0.033
Matrix metalloproteinase-3 0.893 0.522 0.811 0.248 0.615 0.010
All data combined
Baseline
a1-antitrypsin 1.206 0.479 0.567 0.037 1.230 0.436
Intracellular adhesion
molecule-1
1.166 0.484 0.611 0.046 1.451 0.117
Tissue inhibitor of
metalloprotienases-1
0.833 0.583 0.342 0.002 0.843 0.610
von Willebrand factor 0.949 0.775 0.628 0.017 0.760 0.146
Change from baseline to week
4
C-reactive protein 0.910 0.176 0.831 0.011 0.940 0.370
ENRAGE (S100A12) 0.761 0.040 0.710 0.011 0.821 0.135
Interleukin-6 0.953 0.543 0.846 0.039 0.965 0.651
Matrix metalloprotienase-3 0.810 0.173 0.784 0.121 0.669 0.013
Odds ratios show association between biomarker levels (baseline or changes
from baseline to week 4) and whether FACIT-F, SF-36 mental component
summary score, or SF-36 physical component summary score was above or
below the median. Only biomarkers for which at least one association was
<0.05 are shown. FACIT-F, Functional Assessment of Chronic Illness Therapy
-Fatigue; SF-36, 36-question Short Form Survey; OR, odds ratio; MCS, mental
component summary score; PCS, physical component summary score.
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Page 9 of 11N-terminal propeptide of type 1 procollagen; PAI: plasminogen activator
inhibitor; PCS: physical component score; PPV: positive predictive value; RA:
rheumatoid arthritis; SF-36: 36-question Short Form Survey; SGOT: serum
glutamic oxaloacetic transaminase; SHBG: sex hormone-binding globulin;
TIMP: tissue inhibitor of metalloproteinase; TNF-a tumor necrosis factor-a
VEGF: vascular endothelial growth factor.
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